Fol. Biol. 2011, 57, 133-138

https://doi.org/10.14712/fb2011057040133

Effect of PPAR-γ Agonist Rosiglitazone on Bone Mineral Density and Serum Adipokines in C57BL/6 Male Mice

Petr Dan Broulík1, L. Šefc2, M. Haluzík1

1Third Department of Medicine – Department of Endocrinology and Metabolism, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic
2Institute of Pathological Physiology and Centre for Experimental Haematology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic

Received January 2011
Accepted February 2011

References

1. Ackert-Bicknell, C. L., Shockley, K. R., Horton, L. G., LeckaCzernik, B., Churchill, G. A., Rosen, C. J. (2009) Strain specific effects of rosiglitazone on bone mass body composition and serum insulin-like growth factor-I. Endocrinology 150, 1330-1340. <https://doi.org/10.1210/en.2008-0936>
2. Aleo, M., Lundeen, G. R., Blackwell, D. K., Smith, W. M., Coleman, G. L., Stadnicki, S. W., Kluwe, W. M. (2003) Mechanism and implications of brown adipose tissue proliferation in rats and monkeys treated with the thiazolidinedione darglitazone, a potent peroxisome proliferator-activated receptor-γ agonist. J. Pharmacol. Exp. Ther. 305, 1173-1182. <https://doi.org/10.1124/jpet.102.042648>
3. Alli, A. A., Weinstein, R. S., Stewart, S. A., Parfit, A. M., Manolagas, S. C., Jilka, R. L. (2005) Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146, 1226-1235. <https://doi.org/10.1210/en.2004-0735>
4. Arai, F., Yoshihara, H., Hosokawa, K., Nakamura, Y., Gomei, Y., Iwasaki, H., Suda, T. (2002) Niche regulation of hematopoietic stem cells in the endosteum. Ann. N. Y. Acad. Sci. 1176, 36-46. <https://doi.org/10.1111/j.1749-6632.2009.04561.x>
5. Beall, P. T., Misra, L. K., Young, R. L., Spjut, H. J., Evans, H. J., Le Blame, A. (1984) Clomiphene protects against osteoporosis in the mature ovariectomized rat. Calcif. Tissue Int. 36, 123-125. <https://doi.org/10.1007/BF02405304>
6. Boden, G., Cheung, P., Mozzoli, M., Fried, S. K. (2003) Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes. Metabolism 52, 753-759. <https://doi.org/10.1016/S0026-0495(03)00055-6>
7. Chang, K. T., Šefc, L., Pšenák, O., Vokurka, M., Nečas, E. (2005) Early fetal liver readily repopulates B-lymphopoiesis in adult bone marrow. Stem Cells 23, 230-239. <https://doi.org/10.1634/stemcells.2004-0069>
8. Deyhim, F., Garica, K., Lopez, E., Gonzales, J., Ino, S., Garcia, M., Patil, B. S. (2006) Citrus juice modulates bone strength in male senescent rat model of osteoporosis. Nutrition 22, 559-563. <https://doi.org/10.1016/j.nut.2005.12.002>
9. Duncan, D. (1955) Multiple range and multiple F test. Biometrics 11, 1-4. <https://doi.org/10.2307/3001478>
10. Festuccia, W. T., Blanchard, P. G., Turcotte, V., Laplante, M., Sariahmetoglu, M., Brindlay, D. N., Dehales, R. D. (2009) The PPAR-γ agonist rosiglitazone enhances rat brown adipose tissue lipogenesis from glucose without altering glucose uptake. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296, R1327-R1335. <https://doi.org/10.1152/ajpregu.91012.2008>
11. Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., Viberti, G. (2008) Rosiglitazone associated fracture in type 2 diabetes. Diabetes Care 31, 845-851. <https://doi.org/10.2337/dc07-2270>
12. Laharrague, P., Truel, N., Fontanille, A. M., Corberand, J. X., Penicaud, L., Casteilla, L. (2000) Regulation of cytokines of leptin expression in human bone marrow adipocytes. Horm. Metab. Res. 32, 381-385. <https://doi.org/10.1055/s-2007-978658>
13. Lazarenko, O. P., Rzonca, S. O., Suva, L. J., Lecka-Czernik, B. (2006) Netoglitazone is a PPAR-γ a ligand with selective effects on bone and fat. Bone 38, 74-84. <https://doi.org/10.1016/j.bone.2005.07.008>
14. Lazarenko, O. P., Rzonca, S. O., Hogue, W. R., Swain, F. L., Suva, L. J., Lecka-Czernik, B. (2007) Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148, 2669-2680. <https://doi.org/10.1210/en.2006-1587>
15. Mori, Y., Murakawa, Y., Okada, K., Horikoshi, H., Yokoyama, J., Tajima, N., Ikeda, Y. (1999) Effects of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 22, 908-912. <https://doi.org/10.2337/diacare.22.6.908>
16. Okazaki, R. (2000) Skeletal effects of thiazolidinediones. Nippon Rinsho 58, 456-460.
17. Petrovic, N., Shabalina, I. G., Timmons, J. A., Cannon, B., Nedergaard, J. (2008) Thermogenically competent nonadrenergic recruiment in brown preadipocytes by a PPAR-γ agonist. Am. J. Physiol. Endocrinol. Metab. 295, E287-E296. <https://doi.org/10.1152/ajpendo.00035.2008>
18. Rzonca, S. O., Suva, L. J., Gaddy, D., Montague, D. C., Lecka-Czernik, B. (2004) Bone is a target for antidiabetic compound rosiglitazone. Endocrinology 145, 401-406. <https://doi.org/10.1210/en.2003-0746>
19. Schwartz, A. V., Sellmeyer, D. E., Wittinghoff, E., Palermo, L., Lecka-Czernik, B., Feingold, K. R., Strotmeyer, E. S., Resnick, H. E., Carbone, L., Beamer, B. A., Park, S. W., Lane, N. E., Harris, T., Cummings, S. R. (2006) Thiazolidinedione use and bone loss in older diabetic adults. J. Clin. Endocrinol. Metab. 91, 3349-3354. <https://doi.org/10.1210/jc.2005-2226>
20. Schwartz, A. V., Sellmeyer, D. E. (2007) Thiazolidinedione therapy gets complicated. Diabetes Care 30, 1670-1671. <https://doi.org/10.2337/dc07-0554>
21. Soroceanu, M. A., Miao, D., Bai, X. Y., Su, H., Goltzman, D., Karaplis, A. C. (2004) Rosiglitazone impacts negatively on bone by promoting osteoblasts/osteocyte apoptosis. J. Endocrinol. 183, 203-216. <https://doi.org/10.1677/joe.1.05723>
22. Sotoh, N., Ogawa, Y., Usui, T., Tagami, T., Kono, S., Uesugi, H., Sugiyama, H., Sugawara, A., Yamada, K., Shimatsu, A., Kuzuya, H., Nakao, K. (2003) Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26, 2493-2499. <https://doi.org/10.2337/diacare.26.9.2493>
23. Sottile, V., Seuwen, K., Kneissel, M. (2004) Enhanced marrow adipogenesis and bone resorption in estrogen deprived rats treated with the PPAR-γ agonist BRLL49633 (rosiglitazone). Calcif. Tissue Int. 75, 329-227. <https://doi.org/10.1007/s00223-004-0224-8>
24. Thomas, T., Burguera, B. (2002) Is leptin the link between fat and bone mass. J. Bone Miner. Res. 17, 1563-1569. <https://doi.org/10.1359/jbmr.2002.17.9.1563>
25. Tietz, N. W. (1995) Clinical Guide to Laboratory Tests. 3rd ed. pp. 516-519, Saunders Company, Philadelphia, PA.
26. Tornvig, L., Mosekilde, L. I., Justessen, J., Falk, E., Kassem, M. (2001) Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif. Tissue Int. 69, 46-50. <https://doi.org/10.1007/s002230020018>
27. Van Hoof, V. O., Lepoutre, L. G., Hoylaerts, M. F., Chevigne, R., De Broe, M. E. (1988) Improved agarose electrophoretic method for separating alkaline phosphatase isoenzymes in serum. Clin. Chem. 34, 1857-1862. <https://doi.org/10.1093/clinchem/34.9.1853>
28. Vanderschueren, D. E., Vautterck, A. M. H., Suiker, W. J., Wisser, L. P. C., Schot, R., Bouillon, R. (1992) Bone and mineral metabolism in aged male rats. Short and long term effects of androgen deficiency. Endocrinology 130, 2906-2916. <https://doi.org/10.1210/endo.130.5.1572302>
29. Yaturu, S., Bryant, B., Jain, S. K. (2007) Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 30, 1574-1576. <https://doi.org/10.2337/dc06-2606>
30. Watanabe S, Takeuchi Y, Fukumoto S, Fujita H, Nakano T, Fujita T (2003) Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. J. Bone Miner. Metab. 21, 166-171. <https://doi.org/10.1007/s007740300026>
front cover

ISSN 0015-5500 (Print) ISSN 2533-7602 (Online)

Open access journal

Submissions

Archive